About
Adimab is the biopharma industry's partner of choice for therapeutic antibody discovery and protein engineering. Its proprietary yeast-based platform integrates fully human synthetic and immune libraries to efficiently deliver highly specific, stable, and developable antibody candidates across a wide range of formats—including IgGs, HCAbs, bispecifics, multispecifics, and T cell engagers. The end-to-end process covers antigen acquisition, high-throughput library sorting, in-depth hit characterization, and precision engineering, enabling partners to move from target identification to preclinical lead with speed and confidence. AI-guided engineering is also applied to non-antibody proteins and T cell receptors (TCRs), expanding the platform's versatility for complex modalities. Adimab offers multiple collaboration models: funded discovery programs where antibody leads are transferred to the partner, full platform transfer licenses for internal capability building, and non-exclusive program arrangements. Crucially, Adimab maintains no internal pipeline, ensuring complete strategic alignment with each partner's goals. With 140+ biopharma partnerships, 675+ therapeutic programs initiated, 90+ clinical programs, and 6 approved commercial products and BLAs filed, Adimab has a proven track record of translating discovery science into real-world clinical success. The platform is purpose-built for biologics discovery teams at biotech and pharmaceutical companies seeking high-quality, developable therapeutic candidates.
Key Features
- Yeast-Based Antibody Discovery: Proprietary platform using synthetic and immune libraries to identify highly specific, stable, and developable IgGs, HCAbs, and multispecific antibodies.
- AI-Guided Protein & TCR Engineering: Leverages AI to engineer non-antibody proteins and T cell receptors for optimized binding, stability, and expression profiles.
- Multispecific Antibodies & T Cell Engagers: Engineers diverse multispecific formats including T cell engagers designed for function, manufacturability, and clinical scalability.
- End-to-End Discovery Pipeline: Integrated process from antigen acquisition and high-throughput library sorting to hit characterization, lead optimization, and developability assessment.
- Flexible Partnering Models: Offers funded discovery, platform transfer, and non-exclusive program arrangements to match each partner's strategic and operational needs.
Use Cases
- Biopharma companies seeking to discover and optimize therapeutic antibody leads using a proven, high-throughput yeast-based platform.
- Drug developers engineering multispecific antibodies or T cell engagers for oncology and immunology indications.
- Organizations requiring AI-guided protein and TCR engineering for novel modalities beyond standard antibody formats.
- Biotech firms looking to transfer a full antibody discovery and optimization platform in-house via licensing.
- Clinical-stage companies needing developability-focused antibody engineering to advance preclinical candidates toward IND filing.
Pros
- Proven Clinical Track Record: 140+ biopharma partnerships, 90+ clinical programs initiated, and 6 commercial products demonstrate reliable translation from discovery to the clinic.
- No Internal Pipeline Conflict: Adimab maintains no proprietary pipeline, ensuring full strategic alignment with partner goals and unbiased support for each program.
- Comprehensive Modality Coverage: Supports IgGs, HCAbs, bispecifics, multispecifics, T cell engagers, and TCRs—covering virtually all major therapeutic antibody formats.
- AI-Enhanced Engineering: AI-guided engineering accelerates optimization of antibody leads, proteins, and TCRs for improved efficacy and developability.
Cons
- Enterprise-Only Access: Adimab's services are designed for established biopharma and biotech organizations; smaller startups may face high barriers to entry.
- Opaque Pricing: No publicly available pricing — partnership terms are negotiated individually, making cost estimation difficult without direct engagement.
- Specialized Use Case: The platform is narrowly focused on therapeutic antibody discovery, limiting its applicability outside the biopharmaceutical sector.
Frequently Asked Questions
What types of antibody formats does Adimab support?
Adimab supports a wide range of therapeutic antibody formats including IgGs, HCAbs (heavy-chain antibodies), bispecific and multispecific antibodies, T cell engagers, and T cell receptors (TCRs).
Does Adimab have its own internal drug pipeline?
No. Adimab maintains no internal pipeline, which means the company is fully aligned with its partners' interests and focused exclusively on enabling partner success.
What collaboration models does Adimab offer?
Adimab offers funded discovery programs (where leads are transferred to the partner), platform transfer licenses (giving partners access to the full discovery system), and non-exclusive program arrangements.
How does AI factor into Adimab's platform?
AI-guided engineering is used to optimize non-antibody proteins and T cell receptors, accelerating the identification of candidates with improved binding, stability, and expression characteristics.
What is Adimab's track record in bringing programs to the clinic?
Adimab has initiated 675+ therapeutic programs, advanced 90+ to clinical stages, and supported 6 commercial products and BLAs filed, reflecting a strong history of clinical translation.
